RXI-109: Phase IIa started

RXi began the single-blind, U.S. Phase IIa RXI-109-1402 trial to evaluate RXI-109 in up to 50 patients with 1 long hypertrophic scar or 2 scars comparable in length undergoing scar revision surgery. Patients with 1 scar will receive RXI-109 on a portion of the revised scar segment, with a comparably sized length on the opposite end of the excised scar segment left untreated. Patients with 2 scars will receive RXI-109 on a portion of 1 revised scar segment, while the other scar will be left untreated. ...